Jon Kayyem - GenMark Diagnostics Insider

GenMark Diagnostics -- USA Stock  

USD 6.21  0.24  3.72%

Founder and Sr. VP of RandD

Dr. Jon Faiz Kayyem, Ph.D., is serving as Senior Vice President Research and Development of GenMark Diagnostics Inc. Jon Faiz Kayyem, Ph.D. has served as Senior Vice President, Research and Development since June 2013. Dr. Kayyem previously served as the Companys Chief Scientific Officer from August 2010 to June 2013. Dr. Kayyem served as President and Chief Executive Officer of the Company from May 2010 to August 2010. From August 2009 to May 2010, Dr. Kayyem served as President and Chief Executive Officer of Osmetech plc and Chairman of the board of directors of Osmetech plc from January 2009 to August 2009. Dr. Kayyem attended Yale University and received a combined M.S. and B.S. in Molecular Biophysics and Biochemistry in 1985. Dr. Kayyem received his Ph.D. in Molecular Biology in 1991 from The California Institute of Technology
Age: 52  Founder Since 2013  Ph.D    
Kayyem remained at Caltech as a Senior Research Fellow until 1995, when he founded Clinical Micro Sensors to commercialize technical innovations he developed while at Caltech. In 2000, Clinical Micro Sensors was sold to Motorola, Inc., and subsequently purchased by Osmetech plc in 2005. In 2004, Dr. Kayyem left Clinical Micro Sensors and cofounded the biotechnology fund management company, Efficacy Capital Limited, where he served as managing partner until September 2009.

Management Efficiency

The company has return on total asset (ROA) of (36.85) % which means that it has lost $36.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (113.93) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 28.03 M in liabilities with Debt to Equity (D/E) ratio of 39.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. GenMark Diagnostics has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California. GenMark Diagnostics operates under Medical Appliances Equipment classification in USA and traded on NASDAQ General Markets. It employs 517 people.GenMark Diagnostics (GNMK) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 517 people. GenMark Diagnostics is listed under Medical Equipment category by Fama And French industry classification.

GenMark Diagnostics Leadership Team

James McNally, President, MBA
Michael Gleeson, SVP
Kevin OBoyle, Director
Jennifer Williams, SVP
Scott Mendel, CFO, MBA
Ingo Chakravarty, SVP
James Fox, Director
Jon Kayyem, Founder, Ph.D
Eric Stier, President
Michael Kagnoff, Director
Hany Massarany, CEO, MBA
Lisa Giles, Director
Daryl Faulkner, Director

Stock Performance Indicators

Did you try this?

Run Crypto Portfolio Optimizer Now

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
Hide  View All  NextLaunch Crypto Portfolio Optimizer

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Please also check Risk vs Return Analysis. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.